HTG Molecular Diagnostics (HTGM) stock price, revenue, and financials

HTG Molecular Diagnostics market cap is $33.6 m, and annual revenue was $8.55 m in FY 2020

$33.6 M

HTGM Mkt cap, 21-Jul-2021

$8.5 M

HTG Molecular Diagnostics Revenue FY, 2020
HTG Molecular Diagnostics Gross profit (FY, 2020)4.6 M
HTG Molecular Diagnostics Gross profit margin (FY, 2020), %53.3%
HTG Molecular Diagnostics Net income (FY, 2020)-20.9 M
HTG Molecular Diagnostics EBIT (FY, 2020)-19.6 M
HTG Molecular Diagnostics Cash, 31-Dec-202022.4 M
HTG Molecular Diagnostics EV23.8 M
Get notified regarding key financial metrics and revenue changes at HTG Molecular DiagnosticsLearn more
Banner background

HTG Molecular Diagnostics Revenue

HTG Molecular Diagnostics revenue was $8.55 m in FY, 2020

Embed Graph

HTG Molecular Diagnostics Income Statement

Annual

USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

4.0m5.1m14.8m21.5m19.2m8.5m

Revenue growth, %

27%

Cost of goods sold

3.3m4.1m5.0m5.1m8.9m4.0m

Gross profit

706.1k996.8k9.8m16.4m10.3m4.6m

Gross profit Margin, %

17%19%66%76%54%53%

R&D expense

4.6m7.9m10.0m12.6m10.6m6.1m

General and administrative expense

15.0m17.4m17.5m20.0m18.7m18.1m

Operating expense total

19.6m25.3m27.5m32.6m29.3m24.1m

EBIT

(18.9m)(24.3m)(17.7m)(16.2m)(19.0m)(19.6m)

EBIT margin, %

(467%)(474%)(120%)(75%)(99%)(229%)

Interest expense

2.5m1.7m1.2m291.2k

Interest income

85.9k112.4k73.2k715.7k623.4k254.7k

Pre tax profit

(21.4m)(26.0m)(19.0m)(16.5m)(19.3m)(20.9m)

Income tax expense

10.2k10.1k2.9k3.5k3.4k14.4k

Net Income

(21.4m)(26.0m)(19.0m)(16.5m)(19.3m)(20.9m)

HTG Molecular Diagnostics Balance Sheet

Annual

USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

3.3m7.5m10.0m8.4m7.6m22.4m

Accounts Receivable

716.2k1.4m6.4m5.0m3.2m1.6m

Prepaid Expenses

443.1k568.2k633.5k1.1m

Inventories

1.2m1.3m1.3m1.5m

Current Assets

34.9m15.1m17.9m38.0m41.4m32.9m

PP&E

1.9m3.3m3.3m2.4m2.2m1.2m

Total Assets

39.4m18.5m21.3m43.8m45.1m35.2m

Accounts Payable

724.8k761.7k2.4m1.8m1.7m1.3m

Short-term debt

3.7m3.7m

Current Liabilities

6.3m10.0m13.3m7.0m8.9m7.2m

Long-term debt

7.5m8.9m

Non-Current Liabilities

13.5m

Total Debt

11.3m12.6m

Total Liabilities

24.0m24.3m22.7m21.1m20.7m

Common Stock

13.9k28.6k58.1k5.2k

Preferred Stock

24.0

Additional Paid-in Capital

106.6m110.1m131.5m172.1m194.2m205.7m

Retained Earnings

(89.6m)(115.6m)(134.6m)(151.0m)(170.3m)(191.2m)

Total Equity

16.9m(5.6m)(3.1m)21.1m24.0m14.5m

Financial Leverage

2.3 x-3.3 x-6.9 x2.1 x1.9 x2.4 x

Quarterly

USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

1.6m11.2m2.6m4.9m7.5m5.5m2.8m13.4m9.0m20.5m5.8m6.2m7.0m11.8m34.8m10.4m21.0m

Accounts Receivable

852.3k554.2k696.8k574.6k1.9m591.9k1.2m1.6m3.2m2.8m3.5m3.4m3.3m4.0m3.9m1.2m1.0m

Prepaid Expenses

122.1k236.0k223.5k264.7k256.6k226.1k368.6k468.4k527.6k464.6k845.2k688.6k557.5k1.1m854.6k525.6k1.2m

Inventories

2.1m2.4m2.3m2.4m2.2m1.9m1.3m1.3m1.3m1.0m1.0m1.1m1.2m1.2m1.2m1.6m1.4m

Current Assets

4.6m33.4m34.9m33.4m27.7m19.5m8.2m16.7m14.0m50.2m46.1m39.0m30.1m27.8m43.9m38.6m36.5m

PP&E

1.3m1.5m1.8m3.7m4.0m3.7m3.1m2.9m3.3m3.1m2.9m2.6m2.1m2.4m2.2m2.2m1.8m

Total Assets

7.7m49.3m44.5m39.8m31.7m23.2m11.4m19.6m17.2m53.3m49.0m44.9m36.4m35.1m50.9m41.9m39.3m

Accounts Payable

879.0k1.2m966.9k2.2m1.6m1.1m1.2m1.3m2.7m2.2m1.3m1.9m1.4m3.4m3.0m1.7m927.8k

Short-term debt

4.0m1.7m

Current Liabilities

6.5m3.4m4.8m10.5m10.6m9.8m10.1m10.6m13.5m5.1m4.9m5.5m4.8m8.0m8.4m8.4m4.9m

Long-term debt

441.3k976.8k820.9k7.1m11.2m

Non-Current Liabilities

15.5m

Total Debt

441.3k976.8k820.9k11.1m12.9m

Total Liabilities

25.4m21.8m22.1m29.2m27.7m25.4m22.4m21.2m21.8m22.4m21.8m22.1m20.4m23.5m22.8m20.0m20.6m

Common Stock

334.06.8k6.8k7.0k7.1k7.1k8.1k11.4k12.5k28.4k28.4k28.5k28.6k28.7k58.0k62.2k67.1k

Preferred Stock

51.024.0

Additional Paid-in Capital

107.2m107.5m107.8m110.5m125.7m128.1m170.9m171.2m171.7m172.4m172.8m194.0m197.6m200.1m

Retained Earnings

(72.3m)(78.7m)(83.9m)(96.6m)(103.4m)(109.9m)(121.4m)(127.3m)(132.6m)(139.9m)(144.0m)(148.9m)(156.4m)(161.2m)(165.9m)(175.8m)(181.5m)

Total Equity

(74.6m)27.5m22.4m10.6m4.0m(2.2m)(11.0m)(1.5m)(4.5m)31.0m27.2m22.8m16.0m11.7m28.1m21.9m18.7m

Debt to Equity Ratio

0 x0.1 x

Debt to Assets Ratio

0 x0 x

Financial Leverage

-0.1 x1.8 x2 x3.8 x7.9 x-10.5 x-1 x-12.7 x-3.8 x1.7 x1.8 x2 x2.3 x3 x1.8 x1.9 x2.1 x

HTG Molecular Diagnostics Cash Flow

Annual

USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(21.4m)(26.0m)(19.0m)(16.5m)(19.3m)(20.9m)

Depreciation and Amortization

662.6k1.5m1.2m1.5m1.3m1.3m

Accounts Receivable

40.0k(661.2k)(5.0m)1.3m1.8m1.6m

Inventories

(746.2k)(33.2k)77.2k(171.9k)(116.8k)(256.9k)

Accounts Payable

(312.3k)10.1k1.2m(150.2k)(156.0k)(23.8k)

Cash From Operating Activities

(19.2m)(22.2m)(16.6m)(13.2m)(16.7m)(16.3m)

Purchases of PP&E

(1.3m)(1.9m)(1.0m)(949.5k)(1.1m)(453.6k)

Cash From Investing Activities

(32.2m)24.4m3.3m(23.2m)(3.5m)18.7m

Long-term Borrowings

(6.5m)(1.7m)(1.4m)(687.1k)

Cash From Financing Activities

51.1m2.0m15.8m38.1m19.4m9.0m

Net Change in Cash

2.5m1.7m(812.9k)11.5m

Interest Paid

935.0k1.1m698.1k553.1k686.0k869.9k

Income Taxes Paid

2.0k3.5k3.4k17.5k

Quarterly

USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Net Income

(4.1m)(10.5m)(15.7m)(7.0m)(13.9m)(20.4m)(5.8m)(11.7m)(17.0m)(5.4m)(9.5m)(14.3m)(5.4m)(10.2m)(14.9m)(5.5m)(11.2m)

Depreciation and Amortization

151.5k299.4k473.8k357.0k728.8k1.1m296.0k587.5k893.3k356.2k778.3k1.1m309.0k603.5k920.9k348.6k700.3k

Accounts Receivable

(35.0k)213.1k59.4k141.7k(1.2m)124.4k181.3k(173.4k)(1.8m)3.4m2.9m3.0m1.7m1.0m1.1m2.0m2.2m

Inventories

(431.6k)(937.2k)(854.1k)(195.2k)(161.6k)(104.3k)63.2k(19.7k)13.9k127.2k191.8k25.0k103.3k100.9k(11.7k)(375.2k)(120.6k)

Accounts Payable

(69.5k)7.0(254.4k)714.4k799.8k367.5k311.0k480.0k1.5m(78.2k)(656.6k)(123.3k)(480.5k)1.2m928.5k(410.8k)(659.7k)

Cash From Operating Activities

(4.4m)(10.2m)(14.7m)(6.1m)(12.9m)(17.3m)(4.6m)(9.6m)(13.7m)(2.7m)(7.0m)(10.6m)(5.6m)(8.8m)(12.8m)(3.9m)(8.4m)

Purchases of PP&E

(343.7k)(444.3k)(950.3k)(220.6k)(1.6m)(1.9m)(65.4k)(152.3k)(525.4k)(457.8k)(829.2k)(857.9k)(103.3k)(319.4k)(753.4k)(25.2k)(322.4k)

Cash From Investing Activities

(343.7k)(33.3m)(37.4m)2.8m13.7m17.8m1.6m4.1m3.8m(25.5m)(35.6m)(28.2m)4.6m12.8m19.1m4.0m13.4m

Long-term Borrowings

(7.3k)(14.6k)(21.9k)(27.3k)(1.5m)(3.0m)(3.2m)(4.8m)(1.7m)(1.7m)(1.7m)(13.8k)(25.2k)(34.9k)(299.8k)(444.4k)

Dividends Paid

Cash From Financing Activities

2.7m51.1m51.1m5.0m3.5m1.8m(1.7m)11.3m11.5m38.8m38.4m38.3m(465.8k)(637.7k)20.1m2.8m5.1m

Net Change in Cash

(2.0m)7.6m(1.0m)1.6m4.2m2.2m(4.7m)5.9m1.5m10.6m(4.2m)(534.3k)(1.5m)3.4m26.4m2.8m10.1m

Interest Paid

233.8k467.5k701.3k237.4k559.8k850.7k225.7k417.8k575.5k83.4k202.6k369.4k172.0k348.1k521.5k164.0k602.2k

Income Taxes Paid

3.5k3.5k6.8k3.2k6.6k

HTG Molecular Diagnostics Ratios

USDQ1, 2015

Financial Leverage

-0.1 x

HTG Molecular Diagnostics Employee Rating

2.419 votes
Culture & Values
2.3
Work/Life Balance
2.6
Senior Management
2.3
Salary & Benefits
2.6
Career Opportunities
2.4
Source